Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

BACKGROUND: Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Burlando, Martina, Castelli, Riccardo, Cozzani, Emanuele, Parodi, Aurora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152773/
https://www.ncbi.nlm.nih.gov/pubmed/34104197
http://dx.doi.org/10.7573/dic.2021-2-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152773/
https://www.ncbi.nlm.nih.gov/pubmed/34104197
http://dx.doi.org/10.7573/dic.2021-2-6

Ejemplares similares